Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$34.74
▲ $0.21 (+0.6%)
Market data updated: 09/19 06:06 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$34.72 - $35.15
52-Week Range
$23.62 - $35.43
Beta
—
Next Earnings
05.11.2026
Support
$27.86
Resistance
$35.15
GMAB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+23.9% (1Y)
Strengths: 16/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $285.14 vs. price $34.74 (+720.8%)
Fair Value
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.05 (3y annualized return -2.4% / max drawdown 52.0%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
68
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
50
Value
67
Momentum
79
Risk
48
Sentiment
100
Fundamental
74
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Genmab A/S has centered on its strong financial momentum, with a notable upward revision to its 2026 revenue guidance—rising to $4.325–$4.525 billion—driven by robust royalty streams from drugs like Darzalex and Kesimpta. The company also announced a capital increase following employee warrant exercises and plans to participate in major investor conferences in September. Analysts, including BNP Paribas, have expressed optimism, with an "Outperform" rating and a $40 price target, while regulatory scrutiny of its experimental drug, epcoritamab, remains a minor focus.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Genmab A/S ADS. News trend score: 100. Reason: 12 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
38
🎯 Conviction (vs. Emotion)
50
Psychology
76
Fundamentals
74
Technical
79
Valuation
67
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+37%
Market Narrative
57
Fundamental Reality
50
Narrative Gap
+7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant herding behavior suggests traders are aligning with peers after GMAB’s relative outperformance, despite modest momentum. Euphoria lingers due to extreme valuation disconnects and proximity to resistance, while anchoring may reinforce near-term support. The narrative gap is narrow, indicating alignment between market perception and fundamentals. The key question remains whether herding will sustain or if euphoria-driven buying will persist against the backdrop of extreme undervaluation.
Updated: 09/09/2026, 05:04 AM
What could change this?
👥 What the crowd believes
"boosted its full-year 2026 revenue guidance [...] up from its previous outlook [...] underscores the strong commercial momentum across the company’s royalty streams"
"members of its Executive Committee will participate in fireside chats at the following investor conferences"
"Guggenheim analyst [...] maintains Genmab [...] with a Buy and raises the price target from $40 to $42"
"Capital Increase in Genmab as a Result of Employee Warrant Exercise"
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham (Enterprising Investor) — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 7/100
🗣️ Why do they disagree?
The strongest endorsements come from Benjamin Graham’s Enterprising and Defensive screens (scores 100 and 85) and from Samuel Nelson and Thorstein Veblen, whose high marks reflect a deep statistical discount and a favorable cycle position that line up with their value‑oriented doctrines. By contrast, investors who stress quality and growth‑at‑a‑reasonable‑price, such as Philip Fisher (52) and Howard Marks (56), see only moderate appeal, noting that expectations may already be baked in or that the business, while solid, lacks exceptional attributes. More trend‑focused or market‑efficiency thinkers like Jack Schwager (36), the efficient‑market duo (40), and Peter Lynch (14) assign low scores, indicating that the stock does not meet their criteria for clear setups, strong evidence versus an index, or sufficient growth upside. Consequently, based on each investor’s documented principles, the model estimates that valuation‑centric frameworks are optimistic about GMAB, whereas growth‑oriented, cyclical, and market‑timing frameworks are considerably more cautious.
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 85
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 79
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 64
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 53
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 52
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 51
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 42
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 40
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 36
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 23
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 14
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 7
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
93.6%
Operating Margin
28.6%
Net Margin
25.9%
EBITDA Margin
—
ROE
16.5%
ROA
7.5%
ROIC
—
EPS
$15.50
Cash
$1.72B
Total Debt
$5.27B
Current Ratio
2.02
Debt/Equity
0.93
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$34.74
Estimated Fair Value (DCF)
$285.14
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+720.8%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $1.26B | $1.16B |
| 2 | 8.1% | $1.37B | $1.15B |
| 3 | 6.3% | $1.45B | $1.12B |
| 4 | 4.4% | $1.52B | $1.07B |
| 5 | 2.5% | $1.55B | $1.01B |
Base FCF (last actual year)
$1.15B
Terminal Value
$24.50B
Present Value of Terminal Value
$15.92B
Enterprise Value
$21.44B
Net Debt
$3.56B
Equity Value
$17.88B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$94.89
Tangible Book Value per Share (Tangible NAV)
$53.22
Sentiment based on basic keywords (not AI) — 12 positive, 7 neutral, 1 negative out of the last 20 articles.
Benzinga · 16.9.2026
SeekingAlpha · 15.9.2026
Benzinga · 14.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Yahoo · 26.8.2026
Insider Monkey · 26.8.2026
Yahoo · 25.8.2026
GlobeNewswire · 25.8.2026
Insider Monkey · 13.8.2026
24/7 Wall St. · 12.8.2026
MT Newswires · 12.8.2026
GlobeNewswire · 11.8.2026
Yahoo · 7.8.2026
GuruFocus.com · 7.8.2026
Benzinga · 7.8.2026
SeekingAlpha · 7.8.2026
Yahoo · 7.8.2026
Genmab A/S ADS (GMAB) currently has a StockIQ AI score of 68/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
GMAB currently scores 68/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, GMAB's estimated fair value is $285.14, which is 720.8% above the current price of $34.74. This is one valuation model among several signals in the fair-value category, not a price target.
GMAB's technical score is 79/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $285.14 vs. price $34.74 (+720.8%); Current ratio: 2.02; Price is above the 50-day average.
Based on the real signals StockIQ computed: Calmar: -0.05 (3y annualized return -2.4% / max drawdown 52.0%); Earnings per share (EPS) growth: -12.3%; Net income growth: -15.0%.
StockIQ has no recorded dividend payment history for GMAB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 11 purchases and 0 sales out of the last 11 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| GENMAB A/S | Open Market Purchase | 29.12.2025 | 1,052,806 | +1,052,806 | $97.00 |
| GENMAB A/S | Open Market Purchase | 29.12.2025 | 75,867,199 | -75,867,199 | $97.00 |
| GENMAB A/S | Open Market Purchase | 26.12.2025 | 142,610 | +142,610 | $97.00 |
| GENMAB A/S | Open Market Purchase | 26.12.2025 | 2,978 | +2,978 | $97.00 |
| GENMAB A/S | Open Market Purchase | 24.12.2025 | 96,082 | +96,082 | $97.00 |
| GENMAB A/S | Open Market Purchase | 23.12.2025 | 561,042 | +561,042 | $97.00 |
| GENMAB A/S | Open Market Purchase | 22.12.2025 | 15,710 | +15,710 | $97.00 |
| GENMAB A/S | Open Market Purchase | 19.12.2025 | 66,264 | +66,264 | $97.00 |
| GENMAB A/S | Open Market Purchase | 18.12.2025 | 212,177 | +212,177 | $97.00 |
| GENMAB A/S | Open Market Purchase | 17.12.2025 | 150,795 | +150,795 | $97.00 |
| GENMAB A/S | Open Market Purchase | 16.12.2025 | 120,752 | +120,752 | $97.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
6,830,174 shares short as of 2026-08-31 · vs. 7,387,972 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.1% of trading volume this week was short selling, vs. 36.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology